Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study

Ceccarelli, Andrea; Scrimaglia, Susan; Fossi, Virginia; Ceccaroni, Luigi; Federici, Andrea; Reali, Chiara; Angelini, Raffaella; Silvestrini, Giulia; Sintoni, Francesco; Fantini, Maria Pia; Gori, Davide; Righi, Francesca; Montalti, Marco

doi:10.3390/vaccines10101770

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aggregate data concerning the uptake achieved during the 2022 catch-up campaign were obtained from a previous research effort conducted by the research team [ 21 ]. Additionally, aggregated data (by cohort and gender) concerning the overall coverage rates achieved for each cohort across all four centers in 2022 and the early months of 2023 were extracted from the vaccination registry of the Romagna LHA.…”

Section: Methodsmentioning

confidence: 99%

“…Aligned with the national vaccination program, the Romagna Local Health Authority (LHA) conducts an annual HZ vaccination campaign specifically targeting individuals who are turning 65 in the respective year and have not previously received the vaccine. During 2022, a catch-up campaign, which concentrated on cohorts born in 1955, 1956, and 1957, was carried out due to missed calls during the COVID-19 pandemic, achieving in the Romagna LHA an adherence rate of 11.4–12.4% [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy

Ceccarelli,

Tamarri,

Angelini

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

The Herpes Zoster (HZ) vaccination has proven both safe and effective in alleviating conditions related to HZ, leading to significant cost savings in national healthcare and social systems. In Italy, it is recommended and provided free of charge to individuals aged 65 and older. To achieve broad vaccination coverage, alongside ordinary immunization campaigns, active and catch-up campaigns were implemented. This retrospective observational study aimed to observe the vaccination coverage achieved in the Romagna Local Health Authority (LHA) during the 2023 active campaign, with a secondary goal of assessing the impact of the 2022 catch-up campaign and the 2023 active campaign compared to ordinary campaigns. As of 3 July 2023, an overall vaccine uptake of 13.5% was achieved among individuals born in 1958, with variations among the four LHA centers ranging from 10.2% to 17.7%. Catch-up and active campaigns together contributed to nearly half of the achieved coverage in Center No. 1 and a quarter in Center No. 2. Notably, individuals born in 1957, not included in the Center No. 2 catch-up campaign, reached significantly lower vaccination coverage compared to other cohorts and centers. Analyzing the use of text messages for active campaigns, it was observed that cohort groups did not show substantial differences in text-message utilization for warnings. However, having relatives who had experienced HZ-related symptoms significantly reduced the reliance on text messages as warnings. These results highlighted how catch-up and active campaigns effectively increased vaccine coverage. Nevertheless, differences in uptake among different centers within the same LHA and the limited contribution of other information sources compared to text messages suggest the necessity of designing campaigns involving all available channels and stakeholders to maximize vaccine uptake.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy

Ceccarelli,

Tamarri,

Angelini

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…The recent rise in cases brings attention to the importance of managing the low vaccination rate, which is attributed to public beliefs and perceptions toward HZ and its vaccination [ 8 ]. Despite the fact that vaccination of HZ is available as a preventive measure for shingles, the vaccination rate in Saudi Arabia is still low, reaching around 5% of the target population [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…Studies have suggested that the reasons for vaccine hesitancy include insufficient information about the diseases, uncertainty about the safety and efficacy of the vaccine, and other cultural factors [ 8 ]. A few studies have suggested a limited awareness of HZ and its vaccination among the Saudi population.…”

Section: Introductionmentioning

confidence: 99%

Public Perception in Saudi Arabia Toward Herpes Zoster and Its Vaccination: A Cross-Sectional Study

AlKhowailed,

Alotaibi,

Aljurays

et al. 2024

Cureus

View full text Add to dashboard Cite

Background Herpes zoster (HZ) or shingles, arises from the reactivation of the varicella zoster virus (VZV), mainly affecting older and immunocompromised individuals. Despite the efficacy of vaccines, vaccination rates in Saudi Arabia are low. Thus, this study aimed to assess the knowledge, attitude, and practice of the Saudi Arabian population toward HZ and its vaccination. Methods An observational cross-sectional study was carried out to evaluate the public perception in Saudi Arabia toward HZ and its vaccination, during the period from January to March 2024. Participants were selected using a non-probability, convenience sampling method, with recruitment facilitated through WhatsApp, a messaging app. Data has been analyzed using the statistical software Statistical Package for Social Sciences (SPSS), version 26.0 (IBM Corp., Armonk, NY). A p-value of <0.05 has been used to report the statistical significance. Results The study's demographic profile included 1237 participants, predominantly younger than 30 years (65.5%), with a female majority (65.7%). Public knowledge about HZ was limited, only 29.6% of participants recognized the risk of HZ post-chickenpox. More than half of the participants were not aware that the vaccine is provided by the Saudi Ministry of Health (MOH) for certain groups. However, over 75% are willing to receive the HZ vaccine upon physician recommendation. Conclusion This study shows a general lack of awareness about HZ and its vaccination in Saudi Arabia, including misconceptions about vaccination availability, recommendations, and the disease's complications. Gender differences in attitude and interest highlight the potential for tailored educational campaigns. Addressing these issues is essential for improving vaccination rates and mitigating HZ's impact.

show abstract

“…Based on these results, the Advisory Committee on Immunization Practices USA recommends RZV, rather than LZV, in patients with diabetes older than 50 years [ 26 ]. RZV is also being increasingly recommended in national vaccination guidelines across Europe and Canada [ 27 – 29 ].Nevertheless, HZ vaccine coverage is still suboptimal, likely due not only to logistic and economic difficulties [ 30 ], but also to the lack of physician recommendations [ 31 ], although some virtuous experiences have been reported [ 32 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: a systematic review and meta-analysis of clinical trials and observational studies

Silverii

Clerico

Fornengo³

et al. 2023

Acta Diabetol

View full text Add to dashboard Cite

Aim The risk for Herpes zoster (HZ) and its complications is higher in people with diabetes mellitus (DM). Our aim is to assess efficacy and effectiveness of the currently available live-attenuated zoster vaccine (LZV) and recombinant zoster vaccine (RZV) in adults with DM. Methods A Systematic Review and Meta-analysis of clinical trials and observational studies comparing incidence of HZ and its complications in vaccinated and unvaccinated people with DM was performed, on PubMed, Cochrane, Clinical Trials.gov and Embase databases, up to January 15th, 2023. Risk of bias was assessed through the Cochrane Collaboration tool and the Newcastle–Ottawa Scale. The protocol was registered on the PROSPERO website (CRD42022370705). Results Only three observational studies reported LZV efficacy and effectiveness in people with DM. A lower risk for HZ infection (MH-OH Ratio 95% CI = 0.52 [0.49, 0.56] was observed, for unadjusted analysis, and 0.51 [0.46, 0.56] for adjusted analysis, both with P < 0.00001 and no heterogeneity). No data on LZV safety were reported. A pooled analysis of two trials comparing RZV and placebo, showed a reduced risk for HZ incidence: (95% CI Odds Ratio: 0.09 [0.04–0.19]), with no difference in severe adverse events and mortality. Conclusions In our meta-analysis of three observational studies LZV showed a 48% effectiveness in reducing HZ incidence in adults with diabetes whereas in a pooled analysis of two RCTs, RZV showed a 91% efficacy. No data are available on the effects of vaccination on the incidence and severity of HZ-related complications among subjects with diabetes.

show abstract

Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study

Cited by 5 publications

References 27 publications

Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy

Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy

Public Perception in Saudi Arabia Toward Herpes Zoster and Its Vaccination: A Cross-Sectional Study

Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: a systematic review and meta-analysis of clinical trials and observational studies

Contact Info

Product

Resources

About